UNITHER acquired by IK PARTNERS
Context
Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.
It is worth noting that the fund Ardian took control of Unither through an LBO in 2017.
UNITHER, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Global leader in sterile unit-dose manufacturing using Blow-Fill-Seal (BFS) technology. The group provides contract development and manufacturing services for pharmaceutical companies, specializing in ophthalmology, respiratory diseases, and saline solutions.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Other operations with UNITHER
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2017 | ARDIAN | UNITHER | FRANCE | CDMO |
REFERENCES
Valuation range: EV 1b - 4b EUR
Revenue range: 250M - 500M EUR
EBITDA range: 50M - 100M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNITHER by IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: ik partners